EMPLOYMENT AGREEMENTEmployment Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this 6th day of April, 2004 (the “Effective Date”), between Tibor Keler (the “Executive”) and CELLDEX THERAPEUTICS, INC. (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). In consideration of the mutual promises and agreements contained herein, the Parties agree as follows:
EMPLOYMENT AGREEMENTEmployment Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this 5th day of April 2006 (the “Effective Date”), between DR. THOMAS DAVIS, whose principal residence is located at 6275 Firethorn Lane, Clarksville, Maryland 21029 (the “Executive”), and CELLDEX THERAPEUTICS, INC., with its principal place of business located at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey 08865 (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). In consideration of the mutual promises and agreements contained herein, the Parties agree as follows:
AGREEMENT OF LEASELease Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS AGREEMENT OF LEASE made this 21st day of October, 2005 by and between PHILLIPSBURG ASSOCIATES, L.P., a Pennsylvania limited partnership (hereinafter called “Landlord”), and CELLDEX THERAPEUTICS, INC. a Delaware corporation (hereinafter called “Tenant”).
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of April 6, 2004 (the “Effective Date”), is entered by and between MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (collectively, “Medarex”), and CELLDEX THERAPEUTICS, INC., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”).
ContractSupply Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Delaware
[ **** ] indicates confidential portions have been redacted and submitted separately pursuant to confidentiality request with the Commission
SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • North Carolina
This agreement (“AGREEMENT”), dated as of May 1, 2004 is between DUKE UNIVERSITY (“DUKE”), a North Carolina non-profit corporation, located in Durham, North Carolina, and MEDAREX, INC., (“SPONSOR”), having offices at 707 State Road, Suite 206, Princeton, New Jersey 08540-1437.
ASSIGNMENT AND LICENSE AGREEMENTAssignment and License Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS ASSIGNMENT AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of April 6, 2004 (the “Effective Date”), by and between CELLDEX THERAPEUTICS, INC., having principal offices at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”), MEDAREX, INC., having principal offices at 707 State Road, Princeton, New Jersey 08540-1437 (“MI”), and GENPHARM INTERNATIONAL, INC., a wholly-owned subsidiary of MI having principal offices at 521 Cottonwood Drive, Milpitas, California 95035 (“GPI” and together with MI, “Medarex”). Celldex and Medarex each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CLINICAL TRIAL RESEARCH AGREEMENTClinical Trial Research Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • North Carolina
This Agreement is entered into as of the last date on the signature page hereof (“Effective Date”), by and between DUKE UNIVERSITY, a nonprofit educational and health care institution located at Office of Grants and Contracts, DUMC Box 3001, 107 Seeley G. Mudd Building, Durham, NC 27710, hereinafter called “Institution,” and MEDAREX, INC., a New Jersey corporation with its principal place of business located at 707 State Road, Suite 206, Princeton, New Jersey 08540-1437, hereinafter called “Medarex”.
SEPARATION AND MUTUAL RELEASE AGREEMENTSeparation and Mutual Release Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS SEPARATION AND MUTUAL RELEASE AGREEMENT (this “Agreement”) is entered into by and among DR. ROBERT F. BURNS (the “Executive”), with an address at The Garden House, Red Copse Lane, Boars Hill, Oxford, OX1 5ER, United Kingdom; and CELLDEX THERAPEUTICS, INC. (the “Employer”), with its principal place of business located at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey 08865, and together with its parents, divisions, affiliates, and subsidiaries and their respective officers, directors, employees, shareholders, members, partners, plan administrators, attorneys, and agents, as well as any predecessors, future successors or assigns or estates of any of the foregoing (collectively referred to herein as the “Company”).
LICENSE AGREEMENTLicense Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
THIS LICENSE AGREEMENT (the “Agreement”) is made as of September 1, 2006 (the “Effective Date”) between Duke University, a North Carolina corporation with offices at 2020 West Main Street, Suite 101, Durham, North Carolina 27705, and its Affiliates (“Duke”), and Celldex Therapeutics, Inc., a Delaware corporation with a business address at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey 08865 (“Celldex”). Celldex and Duke each may be referred to herein individually as a “Party” or collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
This License Agreement (“Agreement”) is between The Rockefeller University, a New York nonprofit corporation, with offices located at 1230 York Avenue, New York, NY 10021 (“Rockefeller”), and Celidex Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Company”), having a place of business at 519 Route 173W, Bloomsbury, New Jersey 08804.
ContractAgreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
[ **** ] indicates confidential portions have been redacted and submitted separately pursuant to confidentiality request with the Commission
